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Background: Worldwide more than one million women are annually diagnosed with breast cancer. A considerable
fraction of these women receive systemic adjuvant therapy; however, some are cured by primary surgery and
radiotherapy alone. Prognostic biomarkers guide stratification of patients into different risk groups and hence
improve management of breast cancer patients. Plasma levels of Matrix Metalloproteinase-9 (MMP-9) and its
natural inhibitor Tissue inhibitor of metalloproteinase-1 (TIMP-1) have previously been associated with poor
patient outcome and resistance to certain forms of chemotherapy. To pursue additional prognostic information
from MMP-9 and TIMP-1, the level of the MMP-9 and TIMP-1 complex (MMP-9:TIMP-1) was investigated in plasma
from breast cancer patients.
Methods: Detection of protein:protein complexes in plasma was performed using a commercially available ELISA
kit and, for the first time, the highly sensitive in-solution proximity ligation assay (PLA). We screened plasma from
465 patients with primary breast cancer for prognostic value of the MMP-9:TIMP-1 complex. Both assays were
validated and applied for quantification of MMP-9:TIMP-1 concentration. In this retrospective study, we analyzed
the association between the concentration of the MMP-9:TIMP-1 complex and clinicopathological data and disease
free survival (DFS) in univariate and multivariate survival analyses.
Results: Following successful validation both assays were applied for MMP-9:TIMP-1 measurements. Of the
clinicopathological parameters, only menopausal status demonstrated significant association with the MMP-9:TIMP-1
complex; P = 0.03 and P = 0.028 for the ELISA and PLA measurements, respectively. We found no correlation
between the MMP-9:TIMP-1 protein complex and DFS neither in univariate nor in multivariate survival analyses.
Conclusions: Despite earlier reports linking MMP-9 and TIMP-1 with prognosis in breast cancer patients, we here
demonstrate that plasma levels of the MMP-9:TIMP-1 protein complex hold no prognostic information in primary
breast cancer as a stand-alone marker. We demonstrate that the highly sensitive in-solution PLA can be employed
for measurements of protein:protein complexes in plasma.
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Breast cancer is a frequently occurring malignancy,
which in 2008 affected 1.38 million women worldwide
[1]. In the treatment of breast cancer patients classical
clinicopathological parameters together with estrogen (ER)
and progesterone receptor (PR) and human epidermal
growth factor receptor-2 (HER2) status are currently
applied to stratify patients into high and low risk groups
[2]. Presently, most high-risk breast cancer patients are
offered systemic adjuvant therapy; however, a significant
number of these patients are not in need of this treatment
as they are cured by primary surgery and, in some cases,
adjuvant radiotherapy [2,3]. Introduction of additional and
validated prognostic biomarkers could add information to
current risk stratifications resulting in a more effective
management of future breast cancer patients.
Concentrations of both Matrix metalloproteinase-9
(MMP-9) and the naturally occurring Matrix metalloprotein-
ase (MMP) inhibitor, Tissue inhibitor of metalloproteinases-1
(TIMP-1), have been investigated as tumor biomarkers in
breast cancer [4-8]. MMP-9 belongs to the family of matrix
degrading proteases, which play a role in both physiological
and pathological tissue remodeling, including cancer growth
and dissemination [9]. MMP-9 is primarily secreted as a
pro-enzyme (pro-MMP-9), which can be activated to the
mature enzyme (MMP-9) upon cleavage by proteinases
[10]. In breast cancer high pre-operative serum MMP-9
concentration or MMP-9 activity in plasma have been
suggested as prognostic markers indicating poor patient
outcome [11-13]. Similar results have been reported for
MMP-9 levels in tumor tissue extracts [14]. TIMP-1 coun-
teracts the proteolytic effect of most MMPs, including pro-
MMP-9 and MMP-9 [9]. Counter intuitively, high plasma
levels of TIMP-1 have also been associated with a worse
outcome in breast cancer patients [15]. Similar results have
been reported for TIMP-1 levels in tumor tissue extract
[4-6,16,17]. The observed association between high TIMP-1
levels and poor prognosis may be explained by the other
functions that have been disclosed for TIMP-1: influence
on cell growth [18,19], angiogenesis [20-22], apoptosis
independently of its MMP-inhibitory functions [23-26],
and on epithelial-mesenchymal transition [27].
The present study rests on the hypothesis that MMP-9:
TIMP-1 complexes carry prognostic information when
measured in plasma; i.e. we hypothesized that combining
the prognostic association of MMP-9 and TIMP-1 by
measuring their complex could potentially give additional
prognostic information. Previous observations from tumor
tissue have indicated that the fraction of TIMP-1 bound in
complexes with other molecules is more closely related
with a poor prognosis than the fraction of TIMP-1 present
as a free molecule [28]. Since measurement of the complex
between the two proteins has never been reported from
breast cancer plasma, our study provides novel insight intothe level of MMP-9:TIMP-1 and prognostic value in breast
cancer plasma.
To oblige the potential of these protein biomarkers we
focused on the necessities of assay optimization and
verification of the potential biomarker. Since no validated
assays for MMP-9:TIMP-1 complex determination in plasma
have been published, we decided to apply two different
antibody based techniques to measure the total amount of
the complex (pro-MMP-9:TIMP-1 and MMP-9:TIMP-1).
The MMP-9:TIMP-1 complex was quantified in preopera-
tively obtained plasma samples from 465 patients with pri-
mary breast cancer using a classical commercially available
sandwich ELISA, which had not been validated for use
with plasma samples by the supplier, and using the
recently developed in-solution Proximity Ligation Assay
(PLA, Figure 1). In brief, PLA employs two primary
antibodies each linked by conjugation to a synthetic
40 nucleotide (nt) oligonucleotide. Oligonucleotides are
designed with a specific sequence for primer targeting in
the flanking 20 base pairs, while the central 20 base pair
sequence is universal and specific for the connector. Upon
simultaneous and proximal binding to a target protein
the two oligonucleotides can be connected by ligation, and
the oligonucleotide strand now forms a PCR amplicon
detectable by quantitative real-time PCR.
Both assays performances were thoroughly validated
with regard to recovery, linearity in plasma dilutions, and
intra- and inter-variation. Except for menopausal status,
no correlation of the MMP-9:TIMP-1 concentration was
demonstrated with clinicopathological parameters. There
was no relation between MMP-9:TIMP-1 and outcome
neither in univariate survival analyses nor when combining
the parameters in a multivariate analysis using the Cox
proportional hazards approach with DFS as endpoint,
suggesting that the MMP-9:TIMP-1 complex has no value
as a stand-alone prognostic marker in breast cancer.
Methods
Patients
Preoperatively obtained EDTA plasma samples were
obtained from women undergoing surgery (mastectomy
or lumpectomy) with sentinel node procedure for primary
breast cancer at Rigshospitalet, Copenhagen, Denmark.
All patients were treated according to the current Danish
Breast Cancer Cooperative Group Guidelines [3]. In the
period 2001 to 2005, 685 samples were collected consecu-
tively according to a standard operating procedure [15].
The present study was conducted as a retrospective study
analyzing 465 plasma samples with both ELISA and
PLA (Figure 2). The median age of the patients was 58 years
(range of 38–80 years). Mean follow-up time was 2450 days
(range 90–3360 days). The endpoint in the statistical
survival analysis was disease free survival (DFS), defined as
survival without recurrence, other malignancy, or death,
Figure 1 Schematic outline of the Proximity Ligation Assay (PLA) technical procedure. A) Schematic outline of the Proximity Ligation Assay
(PLA) technical procedure. PLA probes directed against MMP-9 and TIMP-1 are incubated with the plasma sample allowing a binding of antibodies to
target epitopes. Enzymatic ligations of the two oligonucleotide strands can be carried out only when the two PLA probes are in proximity, due to
complex formation between MMP-9 and TIMP-1. Forming a PCR amplicon the antibody to antigen binding is now converted into a DNA strand, which
can be amplified and later detected by real-time qPCR. B) Principle and sequential design of the MMP-9:TIMP-1 proximity probes. Each polyclonal
antibody (MMP-9 and TIMP-1) has been divided into two pools, with one pool conjugated to the 5’ oligonucleotide (5’end) and the other pool
conjugated to the 3’oligonucleotide (3’end). When mixing MMP-9 (3’end) probe with TIMP-1 (5’end) probe and plasma, the two probes will come
into proximity, if their target antigens form a complex. The connector oligonucleotide is then used to connect the two oligonucleotide arms. Adding
a ligase, the two arms will be ligated together, now forming the template of a PCR amplicon. The flanking 20 base pairs of the conjugated
oligonucleotide represent the unique primer specific sequence, while the central part represents a universal sequence matching the connector
oligonucleotide. The sequences of the specific primers are illustrated in the lower section of the figure. Rew: reverse primer, Frw: forward primer.
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data registered for the patients were provided by the
Danish Breast Cancer Cooperative Group (DBCG)
and are summarized in Table 1. A total of 323 (69%)
patients were postmenopausal. The lymph node status
was known for all 465 patients of which 220 (47%)
had lymph node-positive tumors. The histological types
were divided between 80% ductal carcinomas, 15%
lobular, and 5% other invasive cancers, reflecting a
representative distribution of histological subtypes in
the present cohort. The malignancy grade is only relevant
for ductal or lobular carcinomas, and is consequentlymissing in patients with other invasive cancers. Totally,
134 patients had en event within 10 years after surgery
(recurrence, other malignancy or death as the first event).
For the multivariate analyses only 431 patients were
included, due to missing clinicopathological data in
34 patients, and among these only 124 had an event.
The study was conducted in compliance with the
Helsinki II Declaration and written informed consent was
obtained from all participants. The study was approved
by the local ethical committee of Greater Copenhagen,
approval number: H-4-2012-002. The REMARK Guidelines
[29] were followed wherever applicable.
Figure 2 Consort diagram of patients. Schematic view of the distribution of plasma samples in the present study.
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Blood samples were collected preoperatively following a
standardized protocol [15]. The plasma samples were
prepared by collecting blood in EDTA tubes, which were
placed on ice immediately after sampling. The samples
were centrifuged at 4000 g for 10 minutes and plasma
was transferred to new tubes. Immediately hereafter the
samples were stored at −80°C. The samples analyzed for
TIMP-1:MMP-9 in this study had undergone from one
to four freeze-thaw cycles before analysis.
Assay methods
MMP-9:TIMP-1 analysis by ELISA
Plasma concentrations of MMP-9:TIMP-1 complex were
assayed using a commercially available ELISA (DuoSet®
ELISA Development System, R&D Systems, R&D Systems
Europe Ltd., United Kingdom; Human MMP-9:TIMP-1
complex catalog number DY1449) according to the
manufacturer’s instructions. Before assaying plasma
samples, the assay was validated for measurement of
complexes in plasma. The validation process included
investigations of reproducibility (intra-and inter-assay),
recovery, and linearity upon dilution of samples. Recovery
was determined by adding a fixed amount (1 ng/mL) of
recombinant MMP-9:TIMP-1 complex to a plasma
dilution series. Subsequently, recovery was calculated as
the measured amount of complex in relation to theexpected amount in each sample and reported in per cent.
Intra-assay variation was determined by measurements of
identical samples of a plasma pool diluted 3 times in
reagent diluent buffer on the same plate. Inter-assay
variation was determined by including duplicates of
dilutions of the plasma pool on every plate measured.
Linearity of signal was determined by measuring the signal
in a dilution series of plasma (two-fold serial dilution
ranging from 1-4000 times). Finally, the limit of detection
was determined by repeated measurements of a blank
sample and calculated as the mean of the signal in
these blank samples plus three standard deviations.
For validation purposes, a plasma pool obtained from
a healthy donor plus a pool of plasma from cancer
patients were used. For analysis, the plasma samples
were diluted 3 times.
MMP-9:TIMP-1 analysis by PLA
Proximity probe preparation
The proximity probes directed against MMP-9 and
TIMP-1 were prepared by linking a single batch of affinity
purified polyclonal antibody (MMP-9 (R&D Systems,
Cat.no. AF911) or TIMP-1 (R&D Systems, Cat.no. AF970))
to 3’-hydroxyl free and 5’-phosphate free 40-mer oligo-
nucleotide sequences (Figure 1). Thereby, the unique
amplicons are forming, which are representative for each
target protein. The antibody-oligonucleotide conjugates




N Q1(%) Q2 Q3 Q4 P(χw2 test) Q1(%) Q2 Q3 Q4 P(χw2 test)
Age 0.12 0.27
<50 years 107 30 16 25 21 26 27 24 16
50-69 years 257 50 62 48 60 57 49 56 59
≥70 years 101 20 22 27 19 17 24 20 26
Menopausal status 0.03 0.03
Premenopausal 142 40 22 31 28 36 35 31 20
Postmenopausal 323 60 78 69 72 64 65 69 80
Tumor size 0.96 0.87
0-20 mm 302 66 66 64 64 63 67 63 66
>20 mm 163 34 34 36 36 37 33 37 34
Malignancy grade* 0.06 0.65
Grade 1 196 42 57 41 42 40 49 46 45
Grade 2-3** 239 58 43 59 58 60 51 54 55
Unknown 7
Lymph node status 0.73 0.44
Positive 220 44 47 48 51 42 46 51 51
Negative 245 56 53 52 49 58 54 49 49
Hormone receptor status 0.50 .084
(ER and/or PR) 84
Positive 378 79 86 83 80 82 16 84 80
Negative 82 21 14 17 20 18 16 20
Unknown 5
*malignancy grade is only relevant in ductal or lobularcarcinoma, and therefore missing for 23 patients with other histological types.
**Grade 2: 140, Grade 3: 99.
Association between MMP-9:TIMP-1 complex and the clinicopathological parameters.
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using the Lightning-LinkTM technology. Conjugation quality
was analyzed by SDS-PAGE.
Proximity ligation assay
The basic PLA protocol has previously been described
in details [30]. In brief, 2 μL of a plasma sample was
mixed with 2 μL of plasma dilution buffer (Olink
Bioscience, Sweden) including 200 pM of GFP as internal
control standard spike-in. The mix was incubated at room
temperature for 20 minutes. Probe mixture contain-
ing Probe Mix Diluent (Olink Bioscience), 1% BSA
(Calbiochem/Merck, Germany) and 0.1% Triton X-100
(Merck, Germany) was added to each sample in a 1:1 ratio
and incubated at 4°C overnight. Then 4 μL probed
sample was mixed with 96 μL Ligation reaction buffer
(Olink Bioscience, available upon request) containing
100 nM connector oligonucleotide and 0.0006 units
of T4 DNA ligase (Fermentas, USA). The ligation wasachieved by incubation at 37°C for 10 minutes, followed
by 10 minutes of heat inactivation at 65°C. Prior to
pre-amplification the connector oligonucleotide was
digested using 1 unit of uracil-DNA excision mix
(Epicenter, USA). Pre-amplification was performed in a
total volume of 25 μl by mixing 20 μl of the ligated
product with 5 μL PCR mix (1× PCR buffer (Invitrogen,
Denmark), 15 mM MgCl2 (Invitrogen), 1 mM dNTP
(Invitrogen), 0.2 μM of each forward and reverse pre-
amplification primer (Figure 1) (Biomers, Germany), and
7.5 units Platinum Taq polymerase (Invitrogen)), using
the same amplification protocol as previously described
[30]. Prior to qPCR, the products were diluted 5-fold in
1× Tris-EDTA buffer.
qPCR was performed on a LightCycler 480 (Roche,
Denmark) using a 384-well format. The diluted DNA
products were mixed with 1.4× Fast Universal Master
Mix (Life Technologies, Denmark), dH2O and 0.05 units
of uracil-DNA excision mix (Epicenter) and incubated
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solution. Seven μL of each sample was then trans-
ferred to each well and mixed with 3 μL of 3 μM primer
(Figure 1) (Biomers), dH2O and 0.8 μM TaqMan probe
(Life Technologies, Denmark) to a total sample volume of
10 μL per well. The thermal cycler program was initiated
with 5 min at 95°C followed by 45 cycles of 15 s at 95°C
and 1 min at 60°C. The time period from initiation of PLA
measurements until end of all incubations was four weeks.
Validation of the MMP-9:TIMP-1 proximity ligation assay
We initiated our validation of the PLA technique as a tool
for measuring protein:protein complex in biological samples
with some basic experiments of protocol optimization. The
performances of the MMP-9 and TIMP-1 probes were
assessed by their ability to measure increasing concentration
of the recombinant proteins. MMP-9 (R&D Systems, Cat.
no. 911-MP-010), TIMP-1 (in-house, purified as [31]), and
complexed MMP-9 and TIMP-1 in PBS + 0.1% BSA were
tested. Probe concentrations of 50, 75, 100 and 200 pM
were tested in order to establish the optimal assay setup,
which gave the lowest background signal and best linear
range for each of the two possible probe combinations. The
incubation time and temperature were tested in two differ-
ent settings, one hour at 37°C and overnight at 4°C. The
effect of pre-amplification was tested in both buffer and
plasma to explore if a less time-consuming protocol could
be applied. Unspecific annealing of the qPCR primers was
tested by incubation with the MMP-9:TIMP-1 probes and
recombinant protein, followed by qPCR on the resulting
amplicon with primers for the total MMP-9, total TIMP-1
or specific primers for the MMP-9:TIMP-1 complex as
positive controls. The dynamic range of the MMP-9:
TIMP-1 complex measurements in human plasma was
evaluated by selecting four different plasma samples from
breast cancer patients. Using the ELISA measurements we
selected two samples with a low level of TIMP-1 and two
with a high level of TIMP-1. This was done to investigate if
the decrease in signal was correlated with the dilution factor,
but also to find the optimal dilution range of the plasma
samples. The precision of the assay was investigated by ana-
lysis of these four samples, four times, on four different days.
Every day, the samples were handled independently and the
standard curves were freshly made. The measurements were
made in quadruples, separated prior to the qPCR. This gave
an estimate of the intra-assay variation within a run on the
qPCR plate. The measurement between days allowed for an
estimate of the inter-assay variation of the assay. For analysis,
the plasma samples were diluted 50 times.
Preparation of internal standards, standard curves, and
samples for recovery studies for the proximity ligation assay
For internal control standard we used recombinant green
fluorescent protein (GFP) (Vector Laboratories, USA),which was spiked in the plasma dilution mix (Olink
Bioscience) and thereby added to all sample incubations.
GFP was diluted in PBS + 0.1% BSA (Calbiochem/Merck,
Denmark) and mixed with the plasma diluent mix to a
final concentration of 10 nM. We used the data from GFP
to evaluate the technical performance of the PLA runs. A
standard curve of the MMP-9:TIMP-1 complex was
made to investigate the linear range of the assay. Also, the
standard curve was used for calculation of the MMP-9:
TIMP-1 concentration of each sample. The recombinant
MMP-9 and TIMP-1 were mixed in PBS + 0.1% BSA to
create the complex standard curve; this ranged from 0.010
to 10 nM. The standard curve was prepared and went
through a PCR run and then divided into aliquots and
stored at −20°C until qPCR run; these standard curves
were loaded to each qPCR plate. Recovery and specificity
studies were made in both PBS + 0.1% BSA, chicken
plasma (GeneTex, USA, Cat.no. GTX73211) and human
plasma. Recombinant proteins were spiked in these three
different materials in the range of 200 pM to 2000 pM.
Statistical analysis
For analysis of association between the level of MMP-9:
TIMP-1 and the clinicopathological parameters and DFS;
defined as survival without recurrence, other malignancy,
or death, when registered as the first event, patients were
divided into four groups of 25% quartiles (Q1: 0-25%, Q2:
25-50%, Q3: 50-75%, Q4: 75-100%) of equal size according
to increasing MMP-9:TIMP-1 level. This was done similarly
for both ELISA and PLA measurements. Associations
between the clinical parameters and MMP-9:TIMP-1
levels were tested by χ2tests. Correlation between ELISA
and PLA measurements were analysed by Pearson correl-
ation coefficient and by estimation of the concordance. The
Kaplan-Meier method was used to estimate survival prob-
abilities in the univariate survival analysis and the groups
were compared by the log rank test. The Cox proportional
hazards model was used for multivariate analysis, including
ELISA measurements of MMP-9:TIMP-1 and all the clini-
copathological parameters: age , menopausal status, tumor
size, lymph node status, hormone receptor status and
malignancy grade. For parameters having more levels, they
were all included in the test for significant effect. Patients
with missing values were excluded from the calculations.
P values less than 5% were considered significant. The SAS
software package was used to analyse the data.
Results
Validation of MMP-9:TIMP-1 ELISA
When performing the MMP-9:TIMP-1 ELISA we obtained
a standard curve in accordance with the datasheet from the
manufacturer. The standard curve covers the range
0.05 ng/mL to 3 ng/mL; however, based on determination
of background signal the functional lower limit of detection
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0.169 ng/mL. Validating the assay, we found linearity of the
signal in plasma diluted up to four times. In addition, we
found that the assay performed well with regard to recovery
of signal when plasma samples were diluted 0–4 times as
we determined a recovery between 98–116%. Finally, the
intra- and inter-assay variations were 4.7% (N= 16) and
19.9% (N = 24), respectively.
Validation of MMP-9:TIMP-1 PLA
The sensitivity was not enhanced with increasing probe
concentration and 50 pM was found to be the optimal
probe concentration (Additional file 1: Figure A). The
complex was measured satisfactorily with both combinations
of the probes. In the analysis of the 465 plasma samples
the MMP-9 (5’phosphate) and TIMP-1 (3’hydroxyl) probe
combination was used due to a slightly better linear range
(Additional file 1: Figure B). The sensitivity of the assay
was increased with 1–2 Cp values by leaving the samples
to incubate with the proximity probe mix over night
at 4°C (Additional file 1: Figure A). Efficiency of the
pre-amplification was demonstrated by analyzing a plasma
dilution curve with and without pre-amplification, which
increased the Cp-value with 15 points (Additional file 1:
Figure A). Thus, the extra variation potentially introduced
by the additional step in the PCR did not outdo the
robustness gained by pre-amplification. This procedure
was investigated in one breast cancer plasma sample with
low and one with a high level of TIMP-1, determined by
ELISA in a previous study [15], and it was found that
implementation of pre-amplification was especially
important when analyzing samples with low levels of
target (data not shown). Signals from unspecific annealing
of the qPCR primers were low and did not interfere with
the specific signal, demonstrating high specificity of the
primers (Additional file 1: Figure A). To assess linearity of
signal and assay performance a standard curve for the
complex in buffer including the whole linear range was
performed (Figure 3). After measuring two plasma samples
with low and two with high TIMP-1, a joint linear range for
both low and high expressing samples was found between
the 1:10 and 1:100 dilutions (Figure 3). A concentration
dependent signal was observed only when both MMP-9
and TIMP-1 antigens were present in the buffer and could
form the MMP-9:TIMP-1 complex, demonstrating the high
specificity of the assay. Further, no unspecific signal and no
signal above background were produced when analysing a
chicken plasma sample (Figure 3).
The recovery was investigated in human control
plasma and was found to be in the range of 80-103%.
The precision and performance of the MMP-9:TIMP-1
proximity assay was investigated by analysing four breast
cancer plasma samples for their levels of MMP-9:TIMP-1
complex and the GFP spike-in. Both the intra-variationwithin one plate and the inter-variation between plates
were calculated. The overall intra-variation was 2.5%
(range: 0.8-6.8% (median: 1.9%)) (N = 16) for the MMP-9:
TIMP-1 measurements in breast cancer plasma, while the
inter-variation between plates was 19.9% (range: 11.3-29.2%
(median: 19.6%)) (N = 16). The variation is given in CV%
based on linearized data. The whole dilution curve was
assessed for each sample, however, only the area corre-
sponding to the final area of measurements for the 465
plasma samples was used when calculating the variation,
which for the MMP-9:TIMP-1 complex is the 1:50 dilution
(Additional file 1: Figure C). Furthermore, these data
also demonstrate that 1–4 freeze/thaw cycles, which corre-
sponds to the number of cycles for the analysed breast
cancer samples, do not affect the levels of MMP-9:TIMP-1
complex, thereby eliminating the concern of complex
degradation upon repeated freeze/thaw cycles.
Comparison of ELISA and PLA methods
Including all 465 samples, the correlation between the
two technical approaches was examined. A Pearson
correlation coefficient of 0.53 (Additional file 2) with a
P-value of <0.001 was found. Thus, sample measurements
demonstrated only a low level of correlation between the
two molecular techniques.
Analysis of EDTA plasma from breast cancer patients and
association to clinicopathological variables
The MMP-9:TIMP-1 complex was measured with ELISA
and with PLA in plasma samples obtained preoperatively
from 465 breast cancer patients (Figure 2). The mean
level of MMP-9:TIMP-1 measured by ELISA in the
465 breast cancer plasma samples was 3.63 ng/mL
(0.11 – 14.77 ng/mL) and the mean level of MMP-9:
TIMP-1 measured by PLA in the 465 breast cancer plasma
samples was 0.35 nM (0.09 – 3.50 nM).
The association between the MMP-9:TIMP-1 complex
and the clinicopathological parameters is summarized in
Table 1 for both the ELISA and PLA measurements.
Menopausal status was significantly associated with
MMP-9:TIMP-1 complex concentration measured by
both ELISA (P = 0.03) and PLA (P = 0.028). No other
clinicopatological parameters were associated with the
plasma MMP-9:TIMP-1 complex (Table 1).
Univariate survival analysis
For survival analysis patients were divided into the
four quartiles as described above. When constructing a
Kaplan-Meier curve to provide insight into the shape
of the survival function, plasma MMP-9:TIMP-1 complex
as determined by ELISA did not significantly predict
a shorter or longer DFS (P = 0.8657) (Figure 4A). In
concordance with the ELISA measurements, the plasma
MMP-9:TIMP-1 complex as determined by PLA did not
Figure 3 Performance of the MMP-9:TIMP-1 proximity ligation assay. A) The dark grey bar represents the specific signal from buffer when
both MMP-9 and TIMP-1 antigens are present. The light grey bar represents the unspecific signal from a buffer sample with only MMP-9 as
spike-in, while the medium grey bar represent the unspecific signal from a buffer sample with only TIMP-1 as spike-in. For all spike-in antigens
the concentration stated on the x-axis applies. Further, the cross-reactivity in chicken plasma was demonstrated to be below buffer level. Values
are reported as raw Cp signals. B) Standard curve for the MMP-9:TIMP-1 complex in PBS + 0.1% BSA buffer. The TIMP-1 (5’probe) and MMP-9
(3’ probe) were incubated with increasing amount of the MMP-9 and TIMP-1 antigens. This curve demonstrates the performance of the assay
by assessing linear range in buffer settings and thereby the correlation between dose and Cp signal. The linear range is illustrated by the dotted
lines and values are reported as raw Cp values. C) Inter-assay variation was determined by measuring the same breast cancer plasma sample on
four different days. The four lines represent the sample measured on four different days (run 1, 2, 3 and 4). Values are reported as raw Cp signals.
D) Plasma dilution curves of the MMP-9:TIMP-1 complex from four different breast cancer patients. Samples A and C have a high level of TIMP-1
protein, while samples B and D have a low level of TIMP-1 protein. The combined linear range was set between the 1:10 and 1:100 dilutions,
illustrated by the dotted lines. Values are reported as raw Cp signal. Error bars represent standard deviation.
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in a Kaplan-Meier analysis (Figure 4B). Other prog-
nostic factors that were significantly associated with
DFS in the univariate analyses were age (P < 0.0001),
tumor size (P = 0.0205), malignancy grade (P = 0.0300),
menopausal status (P = 0.0104), and hormone receptor
status (P = 0.0034), which is in accordance with previous
findings [15].
Multivariate survival analysis
All the clinicopathological parameters and all ELISA
measurements of MMP-9:TIMP-1 were included in the
analysis using the expected best prognostic outcome as
base line for each parameter. From the Cox proportional
hazards analysis neither the ELISA measurements of
MMP-9:TIMP-1 (Q2, Q3, or Q4) nor menopausal status,
tumor size, lymph node status, or malignancy grade
were associated with DFS. However, age (≥ 70 years) andhormone receptor status (negative) were associated with
shorter DFS (P < 0.0001, hazard ratio (HR) = 2.48, 95%
Confidence interval (CI) = 1.63 – 3.77; P = 0.002, hazard
ratio = 0.47, 95% CI = 0.30 – 0.75), respectively (Table 2).
An identical multivariate analysis was performed
employing PLA measurements of the MMP-9:TIMP-1
complex. From the Cox proportional hazards analysis
neither the PLA measurements of MMP-9:TIMP-1 (Q2,
Q3, or Q4) nor menopausal status, tumor size, lymph
node status, or malignancy grade were associated with
DFS. However, also in this model age (≥ 70 years)
and hormone receptor status (negative) were associated with
shorter DFS (P < 0.0001, HR = 2.49, 95% CI = 1.64 – 3.78;
P = 0.002, HR = 0.48, 95% CI = 0.30 – 0.76), respectively
(Table 2). HRs and CIs for the MMP-9:TIMP-1 (PLA)
measurements demonstrate a tendency towards a
continuous decrease in HR with higher complex values,
though at no significant level.
Figure 4 Univariate survival analysis of disease free survival (DFS) in plasma for all 465 patients. A) MMP-9:TIMP-1 measured by ELISA.
B) MMP-9:TIMP-1 measured by PLA. Patients are divided into four groups of equal size (Q1-Q4) according to increasing plasma MMP-9:TIMP-1
levels; Q1 being the group with the lowest level.
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We validated and applied two different MMP-9:TIMP-1
assays and found that both the commercially available
ELISA and the PLA reliably quantified the MMP-9:
TIMP-1 complex concentration in plasma samples
from breast cancer patients. In particular, we report
for the first time that in-solution PLA can be used
for quantification of protein:protein complexes inTable 2 Multivariate analysis using Cox proportional hazards




Q2 vs. Q1 1.08 0.65-1.80
Q3 vs. Q1 1.12 0.68-1.85
Q4 vs. Q1 1.06 0.64-1.77
Age
50-69 years vs. < 50 years 0.82 0.39-1.71
≥ 70 years vs. < 50 years 2.48 1.63-3.77
Menopausal status
Post- vs. premenopausal 1.14 0.58-2.27
Tumor size
>20 mm vs. 0–20 mm 1.25 0.85-1.82
Lymph node status
Positive vs. negative 1.22 0.84-1.77
Hormone receptor status
Positive vs. negative 0.47 0.30-0.75
Malignacy grade
Grade 2 + 3 vs. Grade 1 1.15 0.76-1.75
*34 patients are excluded from the analysis due to missing values for one or moreplasma. Except for menopausal status, no associations
between the MMP-9:TIMP-1 concentration and clini-
copathological parameters were found. Further, there
was no relation between MMP-9:TIMP-1 and outcome
when combining the parameters in a multivariate
analysis, suggesting that the MMP-9:TIMP-1 complex
has no value as a stand-alone prognostic marker in
breast cancer.model on DFS, including only patients with no missing
PLA
P HR 95% Cl P
0.771 0.91 0.56-1.49 0.712
0.652 0.84 0.51-1.38 0.493
0.812 0.76 0.46-1.27 0.294
0.592 0.82 0.39-1.72 0.601
<0.0001 2.49 1.64-3.78 <0.0001
0.705 1.19 0.60-2.36 0.618
0.254 1.24 0.85-1.81 0.261
0.301 1.26 0.87-1.84 0.22
0.002 0.48 0.30-0.76 0.002
0.499 1.14 0.75-1.73 0.536
of the prognostic factors.
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analysis of plasma samples. Thus, we ensured performance
with regard to recovery, linearity in plasma dilutions,
and intra- and inter-variation. Moreover, for the PLA, we
performed specificity experiments using recombinant
antigen solutions with or without the specific antigens
present.
Results obtained by the two different MMP-9:TIMP-1
complex assays were weakly correlated (Pearson correlation
coefficient 0.53, P < 0.001). However, due to different
procedures in the protocols and the fact that different
antibodies are used in the two technical systems, some vari-
ation between ELISA and PLA measurements is expected.
Use of different antibodies, in particular polyclonal anti-
bodies, makes possible identification of various conforma-
tions and, potentially, of different complexes with third
components. However, the overall statistical output was
very similar for the two techniques. Use of the PLA method
offers increased sensitivity when compared to conventional
ELISAs; still, despite increased sensitivity no association
with outcome was found. It should be noted that previous
data on co-precipitation of TIMP-1 and MMP-9 have
demonstrated that antibodies do not interfere with the
complex formation [32].
Measurement of the MMP-9:TIMP-1 protein:protein
complex concentrations in plasma from breast cancer
patients for prognostic purposes has not previously been
described although numerous publications have indicated
that both molecules, when measured individually, are
indicative of patient prognosis [5,6,11,15]. Moreover, a
previous study suggested that when analyzing TIMP-1
in breast cancer tissue, it is the fraction of TIMP-1 in
complex with other molecules that is associated with
poor prognosis [28]. In that study, TIMP-1 present in
tumor tissue in an unbound form appeared not to be
related with a poor outcome, whereas increasing amounts
of complex-bound TIMP-1 was related with a shorter
recurrence-free and overall survival. This relation could
not be confirmed in serum samples, however, the study
included a limited number of samples and was weak-
ened by a number of technical issues [33]. Therefore
we addressed this by studying the complex of TIMP-1
and pro-MMP-9/MMP-9 and in the present study of
465 breast cancer patients we were not able to find
support for the hypothesis that the concentration of
MMP-9:TIMP-1 complexes is indicative of prognosis
in breast cancer patients. It could be speculated that
the complexes in plasma are not necessarily related
to those detected in tumor tissue. It has been shown
that total TIMP-1 levels in plasma and tissue extracts
from breast cancer patients are only weakly correlated
[34], and the current findings suggest that the same
holds true for TIMP-1 complexes. In the study from 2008,
it was concluded that tissue-related TIMP-1 does not gainaccess to the blood stream proportionally with its level in
the tumor and as such plasma TIMP-1 is not a surrogate
marker for tissue TIMP-1. Assuming that complex-bound
TIMP-1 in tissue carries prognostic information, it appears
likewise that plasma MMP-9:TIMP-1 is not a surrogate
marker for complexes present in tissue. It can be speculated
that a fraction of the MMP-9, TIMP-1 and complexes
present in tissue are captured or degraded in the tumor
and therefore never reach the circulation.
However, it should be noted that despite significant
associations between classical prognostic parameters
(age, tumor size, malignancy grade, hormone receptor
status, menopausal status) and DFS in univariate analysis,
only age and hormone receptor status remained significant
in the multivariate analyses. It could be speculated
that this is partly due to the fact that all the high-risk
patients (N = 333) received adjuvant systemic therapy.
Consequently, the outcome for these patients is likely
to be positively affected by the therapy and the result
of our analyses may be biased.
On the assumption that previous findings hold true,
i.e. that MMP-9 and TIMP-1 when measured individually
in plasma are related with prognosis, it follows from our
data that complexes between the two molecules do not
have the same prognostic value. One reason for this could
be the complex binding biology of these two protein
molecules. TIMP-1 binds both pro-MMP-9 and mature
MMP-9 in a 1:1 stoichiometry [28,29,35]. However, a vast
amount of different molecules may bind to TIMP-1
(e.g. most of the MMPs) and to MMP-9 (e.g. the
TIMP-1, -2, -3 and −4); this implies that the complex
formation is not necessarily solely dependent of free
MMP-9 and TIMP-1 and that numerous factors can affect
the formation of the MMP-9:TIMP-1 complex [9,36].
Several functional implications of capturing TIMP-1 as
well as MMP-9 in a complex in plasma could be envisioned.
High levels of both total MMP-9 and total TIMP-1 have
been shown to correlate with adverse prognosis and accord-
ingly, it could be speculated that complexes consisting of
the two proteins would be related to prognosis in a similar
way. A functional role for the complex could also be
imagined, e.g. as a carrier complex or as an aid in protect-
ing both proteins from degradation. Conversely, complex
formation could also be regarded as a potential mechan-
ism for removal of free MMP-9 and TIMP-1 from plasma.
Hence, functional considerations do not point to a simple
biological role for the complex.
Conclusions
In conclusion, we have thoroughly validated and employed
two antibody-based assays for measurement of MMP-9:
TIMP-1 complexes in plasma. Our data support future
use of the highly sensitive, low sample-consuming PLA
for detection of protein:protein complexes in plasma. We
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impact of plasma MMP-9 and TIMP-1 when measured
individually, the complex consisting of these two proteins
is not related with prognosis in this cohort of breast cancer
patients, thus pointing to another biological role of
MMP-9:TIMP-1 complexes in breast cancer patients.Additional files
Additional file 1: Validation of MMP-9:TIMP-1 PLA. Figure A. Validation
of MMP-9:TIMP-1 assay performance. A) Various probe concentrations. Four
different proximity probe concentrations (50, 75, 100 and 200 pM) were
incubated with plasma in different dilutions. The probe concentration of
50 pM demonstrated the best linear range and this was evaluated as
being the optimal protocol. B) Sample and probe incubation. The difference
between incubation of sample and probe mix for one hour at 37°C and ON
at 4°C was tested. An increased sensitivity of 1–2 Cp values was assessed by
ON incubation. C) Test for pre-amplification efficiency. To investigate if a
pre-amplification was increasing the signal in the qPCR, a standard curve
was run with and without pre-amplification. An increase of 15 Cp values
was demonstrated due to pre-amplification illustrating high efficiency.
D) Unspecific annealing of the qPCR primers. The interaction of free
pre-amplification primers on the true signal was evaluated. Primer
number 5 corresponds to MMP-9 and primer number 7 corresponds
to TIMP-1. Only the correct 7–5 primer combination gave a true
signal. The three other combinations gave only background signals.
Figure B Difference between detecting the MMP-9:TIMP-1 complex
with the MMP-9 (5’phosphate) and TIMP-1 (3’hydroxyl) probe combination
versus the TIMP-1 (5’phosphate) and MMP-9 (3’hydroxyl) probe combination.
It was found that the MMP-9 (5’phosphate) and TIMP-1 (3’hydroxyl)
probe combination was performing slightly better. Figure C Dilution
curves of plasma samples A-D analysed by PLA in four different days
for the MMP-9:TIMP-1. These curves were used to calculate both
intra- and inter-assay variation.
Additional file 2: Comparison of ELISA and PLA methods. Pearson
correlation between MMP-9:TIMP-1 (ELISA) and MMP-9:TIMP-1 (PLA).Abbreviations
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